‘Cryocure’, a cryogenic device to treat Piles without surgery

S Singh
S Singh
· 3 min read
Cryocure
Cryocure

Cryocure was launched by the Chief Guest, Dr. T.S. Prabhakar, Director of Health and Family Welfare Services in the presence of Dr. Rajah Vijay Kumar, lead scientist in the development of this technology. Dr. Rajah Vijay Kumar, an eminent Bangalore based scientist and inventor, with 30+ inventions to his credit, has now brought out ‘Cryocure’ – an affordable medical device to treat piles without surgery. Dr. Rajah is also the Global Chairman of Organization de Scalene – a 25 year old, Bangalore-based research center. He describes hemorrhoids, popularly known as ‘piles’ as the next lifestyle aggravated disease.

Dr. Prabhakar in his speech said, “Hemorrhoids is the most misused disease across the world. In India mostly quacks are treating Piles and Fistula. Many lives have been lost and deaths caused due to unqualified treatment of hemorrhoids. With Cryocure, we have a cost-effective cure at home. I wish Cryocure and Organization De Scalene the very best of luck.”

According to Dr. Rajah Vijay Kumar, “Hemorrhoids, or piles, are one of mankind’s most common and nagging disorders. It dates back to the times of Mahabharata, when Shakuni, the maternal uncle of ‘Kauravas’, is believed to have suffered from this disease. Another story recounts how Napoleon Bonaparte was defeated at the battle of Waterloo, as he was bothered by very painful thrombosed hemorrhoids. So intense was the pain on the morning of the battle that he could not command the army leading to his defeat and hence it came to be called the “Piles of Defeat.”

He adds, “Today, Piles is a fast-emerging lifestyle risk, with nearly 330 million people suffering from Hemorrhoids globally. In India alone, 41 million have Piles with 1.2 million new cases reported every year. Nearly 60% of the population in South India suffer silently and seldom disclose their condition.”

Dr. Rajah continues, “Hemorrhoids if untreated can lead to a bigger problem and also pose serious medical risks. Cryocure is a simple tube-like device filled with special Cryogenic memory agent. It is priced reasonably so it is affordable and can cure hemorrhoids without any surgical procedure or side effects. It is also safe for usage among pregnant women, diabetic and heart patients. Hemorrhoids are a common occurrence during pregnancy with nearly 40% pregnant women on the planet suffering from it. For all these reasons, it has received widespread acceptance in North Indian cities,” he explains.

Cryocure is made of unbreakable medical plastic. The device must be frozen for two hours before use. Once removed, the cold Cryocure is dipped in coconut oil or Vaseline for lubrication before inserting into the anus at a temperature of -18 degrees C. The Cryogenic effect causes blood vessels of the hemorrhoids to constrict thus making them shrink. With regular use pain, itching, burning and blood loss gradually disappears. This treatment can be done in the comfort of your home.

 

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk